Skip to main content
Erschienen in: Tumor Biology 5/2013

01.10.2013 | Research Article

XRCC1 codon 280 polymorphism and susceptibility to lung cancer: a meta-analysis of the literatures

verfasst von: Qin-xiang Guo, Wei-hua Yang, Jin-fang Zhai, Fu-cai Han, Chun-yan Wang

Erschienen in: Tumor Biology | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

The X-ray repair cross-complementation group 1 (XRCC1) protein plays an important role in base excision repair, and the genetic polymorphisms in the XRCC1 gene influence its function. XRCC1 codon 280 polymorphism is an Arg-His change in the XRCC1 gene. Many studies were published to investigate the association between XRCC1 codon 280 polymorphism and risk of lung cancer, but the results were inconsistent. We performed a meta-analysis of 16 studies with a total of 18,660 subjects (8,736 cases and 9,924 controls). The pooled odds ratios (OR) and corresponding 95 % confidence intervals (95 % CI) for the gene–disease association were calculated. Overall, there was a significant association between XRCC1 codon 280 polymorphism and increased risk of lung cancer (HisHis vs. ArgArg: OR = 1.53, 95 % CI 1.08–2.16, P = 0.016; HisHis vs. ArgArg/ArgHis: OR = 1.55, 95 % CI 1.10–2.19, P = 0.012). However, subgroup analysis by race failed to confirm the obvious association in Europeans and Asians. Therefore, there is a significant association between XRCC1 codon 280 polymorphism and increased risk of lung cancer. More studies with a large sample are needed to further evaluate the possible race-specific effect in the association above.
Literatur
2.
Zurück zum Zitat Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med. 2004;350:379–92.CrossRefPubMed Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med. 2004;350:379–92.CrossRefPubMed
3.
Zurück zum Zitat Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed
4.
Zurück zum Zitat Fu D, Calvo JA, Samson LD. Balancing repair and tolerance of DNA damage caused by alkylating agents. Nat Rev Cancer. 2012;12:104–20.PubMedCentralPubMed Fu D, Calvo JA, Samson LD. Balancing repair and tolerance of DNA damage caused by alkylating agents. Nat Rev Cancer. 2012;12:104–20.PubMedCentralPubMed
6.
Zurück zum Zitat Ginsberg G, Angle K, Guyton K, Sonawane B. Polymorphism in the DNA repair enzyme XRCC1: utility of current database and implications for human health risk assessment. Mutat Res. 2011;727:1–15.CrossRefPubMed Ginsberg G, Angle K, Guyton K, Sonawane B. Polymorphism in the DNA repair enzyme XRCC1: utility of current database and implications for human health risk assessment. Mutat Res. 2011;727:1–15.CrossRefPubMed
7.
Zurück zum Zitat Horton JK, Watson M, Stefanick DF, Shaughnessy DT, Taylor JA, Wilson SH. XRCC1 and DNA polymerase beta in cellular protection against cytotoxic DNA single-strand breaks. Cell Res. 2008;18:48–63.PubMedCentralCrossRefPubMed Horton JK, Watson M, Stefanick DF, Shaughnessy DT, Taylor JA, Wilson SH. XRCC1 and DNA polymerase beta in cellular protection against cytotoxic DNA single-strand breaks. Cell Res. 2008;18:48–63.PubMedCentralCrossRefPubMed
8.
Zurück zum Zitat Chang JS, Wrensch MR, Hansen HM, Sison JD, Aldrich MC, Quesenberry Jr CP, et al. Base excision repair genes and risk of lung cancer among San Francisco Bay Area Latinos and African-Americans. Carcinogenesis. 2009;30:78–87.PubMedCentralCrossRefPubMed Chang JS, Wrensch MR, Hansen HM, Sison JD, Aldrich MC, Quesenberry Jr CP, et al. Base excision repair genes and risk of lung cancer among San Francisco Bay Area Latinos and African-Americans. Carcinogenesis. 2009;30:78–87.PubMedCentralCrossRefPubMed
9.
Zurück zum Zitat Hung RJ, Brennan P, Canzian F, Szeszenia-Dabrowska N, Zaridze D, Lissowska J, et al. Large-scale investigation of base excision repair genetic polymorphisms and lung cancer risk in a multicenter study. J Natl Cancer Inst. 2005;97:567–76.CrossRefPubMed Hung RJ, Brennan P, Canzian F, Szeszenia-Dabrowska N, Zaridze D, Lissowska J, et al. Large-scale investigation of base excision repair genetic polymorphisms and lung cancer risk in a multicenter study. J Natl Cancer Inst. 2005;97:567–76.CrossRefPubMed
10.
Zurück zum Zitat Kim IS, Lee GW, Kim DC, Kim HG, Kim S, Oh SY, et al. Polymorphisms and haplotypes in the XRCC1 gene and the risk of advanced non-small cell lung cancer. J Thorac Oncol. 2010;5:1912–21.CrossRefPubMed Kim IS, Lee GW, Kim DC, Kim HG, Kim S, Oh SY, et al. Polymorphisms and haplotypes in the XRCC1 gene and the risk of advanced non-small cell lung cancer. J Thorac Oncol. 2010;5:1912–21.CrossRefPubMed
11.
Zurück zum Zitat Li M, Yin Z, Guan P, Li X, Cui Z, Zhang J, et al. XRCC1 polymorphisms, cooking oil fume and lung cancer in Chinese women nonsmokers. Lung Cancer. 2008;62:145–51.CrossRefPubMed Li M, Yin Z, Guan P, Li X, Cui Z, Zhang J, et al. XRCC1 polymorphisms, cooking oil fume and lung cancer in Chinese women nonsmokers. Lung Cancer. 2008;62:145–51.CrossRefPubMed
12.
Zurück zum Zitat Ratnasinghe D, Yao SX, Tangrea JA, Qiao YL, Andersen MR, Barrett MJ, et al. Polymorphisms of the DNA repair gene XRCC1 and lung cancer risk. Cancer Epidemiol Biomark Prev. 2001;10:119–23. Ratnasinghe D, Yao SX, Tangrea JA, Qiao YL, Andersen MR, Barrett MJ, et al. Polymorphisms of the DNA repair gene XRCC1 and lung cancer risk. Cancer Epidemiol Biomark Prev. 2001;10:119–23.
13.
Zurück zum Zitat Yin J, Vogel U, Ma Y, Qi R, Sun Z, Wang H. The DNA repair gene XRCC1 and genetic susceptibility of lung cancer in a northeastern Chinese population. Lung Cancer. 2007;56:153–60.CrossRefPubMed Yin J, Vogel U, Ma Y, Qi R, Sun Z, Wang H. The DNA repair gene XRCC1 and genetic susceptibility of lung cancer in a northeastern Chinese population. Lung Cancer. 2007;56:153–60.CrossRefPubMed
14.
Zurück zum Zitat Yin J, Vogel U, Ma Y, Qi R, Wang H. Association of DNA repair gene XRCC1 and lung cancer susceptibility among nonsmoking Chinese women. Cancer Genet Cytogenet. 2009;188:26–31.CrossRefPubMed Yin J, Vogel U, Ma Y, Qi R, Wang H. Association of DNA repair gene XRCC1 and lung cancer susceptibility among nonsmoking Chinese women. Cancer Genet Cytogenet. 2009;188:26–31.CrossRefPubMed
15.
Zurück zum Zitat Zienolddiny S, Campa D, Lind H, Ryberg D, Skaug V, Stangeland L, et al. Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. Carcinogenesis. 2006;27:560–7.CrossRefPubMed Zienolddiny S, Campa D, Lind H, Ryberg D, Skaug V, Stangeland L, et al. Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. Carcinogenesis. 2006;27:560–7.CrossRefPubMed
16.
Zurück zum Zitat De Ruyck K, Szaumkessel M, De Rudder I, Dehoorne A, Vral A, Claes K, et al. Polymorphisms in base-excision repair and nucleotide-excision repair genes in relation to lung cancer risk. Mutat Res. 2007;631:101–10.CrossRefPubMed De Ruyck K, Szaumkessel M, De Rudder I, Dehoorne A, Vral A, Claes K, et al. Polymorphisms in base-excision repair and nucleotide-excision repair genes in relation to lung cancer risk. Mutat Res. 2007;631:101–10.CrossRefPubMed
17.
Zurück zum Zitat Hao B, Miao X, Li Y, Zhang X, Sun T, Liang G, et al. A novel t-77c polymorphism in DNA repair gene XRCC1 contributes to diminished promoter activity and increased risk of non-small cell lung cancer. Oncogene. 2006;25:3613–20.CrossRefPubMed Hao B, Miao X, Li Y, Zhang X, Sun T, Liang G, et al. A novel t-77c polymorphism in DNA repair gene XRCC1 contributes to diminished promoter activity and increased risk of non-small cell lung cancer. Oncogene. 2006;25:3613–20.CrossRefPubMed
18.
Zurück zum Zitat Hung RJ, Christiani DC, Risch A, Popanda O, Haugen A, Zienolddiny S, et al. International lung cancer consortium: pooled analysis of sequence variants in DNA repair and cell cycle pathways. Cancer Epidemiol Biomark Prev. 2008;17:3081–9.CrossRef Hung RJ, Christiani DC, Risch A, Popanda O, Haugen A, Zienolddiny S, et al. International lung cancer consortium: pooled analysis of sequence variants in DNA repair and cell cycle pathways. Cancer Epidemiol Biomark Prev. 2008;17:3081–9.CrossRef
19.
Zurück zum Zitat Misra RR, Ratnasinghe D, Tangrea JA, Virtamo J, Andersen MR, Barrett M, et al. Polymorphisms in the DNA repair genes XPD, XRCC1, XRCC3, and APE/ref-1, and the risk of lung cancer among male smokers in Finland. Cancer Lett. 2003;191:171–8.CrossRefPubMed Misra RR, Ratnasinghe D, Tangrea JA, Virtamo J, Andersen MR, Barrett M, et al. Polymorphisms in the DNA repair genes XPD, XRCC1, XRCC3, and APE/ref-1, and the risk of lung cancer among male smokers in Finland. Cancer Lett. 2003;191:171–8.CrossRefPubMed
20.
Zurück zum Zitat Schneider J, Classen V, Bernges U, Philipp M. XRCC1 polymorphism and lung cancer risk in relation to tobacco smoking. Int J Mol Med. 2005;16:709–16.PubMed Schneider J, Classen V, Bernges U, Philipp M. XRCC1 polymorphism and lung cancer risk in relation to tobacco smoking. Int J Mol Med. 2005;16:709–16.PubMed
21.
Zurück zum Zitat Shen M, Berndt SI, Rothman N, Mumford JL, He X, Yeager M, et al. Polymorphisms in the DNA base excision repair genes APEX1 and XRCC1 and lung cancer risk in Xuan Wei, China. Anticancer Res. 2005;25:537–42.PubMed Shen M, Berndt SI, Rothman N, Mumford JL, He X, Yeager M, et al. Polymorphisms in the DNA base excision repair genes APEX1 and XRCC1 and lung cancer risk in Xuan Wei, China. Anticancer Res. 2005;25:537–42.PubMed
22.
Zurück zum Zitat Vogel U, Nexo BA, Wallin H, Overvad K, Tjonneland A, Raaschou-Nielsen O. No association between base excision repair gene polymorphisms and risk of lung cancer. Biochem Genet. 2004;42:453–60.CrossRefPubMed Vogel U, Nexo BA, Wallin H, Overvad K, Tjonneland A, Raaschou-Nielsen O. No association between base excision repair gene polymorphisms and risk of lung cancer. Biochem Genet. 2004;42:453–60.CrossRefPubMed
23.
Zurück zum Zitat Wang N, Wu YJ, Zhou XL, Wu YM. The polymorphisms of XRCC1 gene and susceptibility to pulmonary cancer. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2012;30:41–4.PubMed Wang N, Wu YJ, Zhou XL, Wu YM. The polymorphisms of XRCC1 gene and susceptibility to pulmonary cancer. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2012;30:41–4.PubMed
25.
Zurück zum Zitat DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.CrossRefPubMed DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.CrossRefPubMed
26.
Zurück zum Zitat Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed
28.
Zurück zum Zitat Campalans A, Marsin S, Nakabeppu Y, O’Connor TR, Boiteux S, Radicella JP. XRCC1 interactions with multiple DNA glycosylases: a model for its recruitment to base excision repair. DNA Repair (Amst). 2005;4:826–35.CrossRef Campalans A, Marsin S, Nakabeppu Y, O’Connor TR, Boiteux S, Radicella JP. XRCC1 interactions with multiple DNA glycosylases: a model for its recruitment to base excision repair. DNA Repair (Amst). 2005;4:826–35.CrossRef
29.
Zurück zum Zitat Jensen LH, Kuramochi H, Cruger DG, Lindebjerg J, Kolvraa S, Danenberg P, et al. Gene expression of the mismatch repair gene MSH2 in primary colorectal cancer. Tumour Biol. 2011;32:977–83.CrossRefPubMed Jensen LH, Kuramochi H, Cruger DG, Lindebjerg J, Kolvraa S, Danenberg P, et al. Gene expression of the mismatch repair gene MSH2 in primary colorectal cancer. Tumour Biol. 2011;32:977–83.CrossRefPubMed
30.
Zurück zum Zitat Symington LS, Gautier J. Double-strand break end resection and repair pathway choice. Annu Rev Genet. 2011;45:247–71.CrossRefPubMed Symington LS, Gautier J. Double-strand break end resection and repair pathway choice. Annu Rev Genet. 2011;45:247–71.CrossRefPubMed
31.
Zurück zum Zitat Kumar A, Pant MC, Singh HS, Khandelwal S. Reduced expression of DNA repair genes (XRCC1, XPD, and OGG1) in squamous cell carcinoma of head and neck in North India. Tumour Biol. 2012;33:111–9.CrossRefPubMed Kumar A, Pant MC, Singh HS, Khandelwal S. Reduced expression of DNA repair genes (XRCC1, XPD, and OGG1) in squamous cell carcinoma of head and neck in North India. Tumour Biol. 2012;33:111–9.CrossRefPubMed
32.
Zurück zum Zitat Zeng FR, Ling Y, Yang J, Tian XC, Yang X, Luo RC. X-ray repair cross-complementing group 1 Arg399gln gene polymorphism and susceptibility to colorectal cancer: a meta-analysis. Tumour Biol. 2013;34:555–63.CrossRefPubMed Zeng FR, Ling Y, Yang J, Tian XC, Yang X, Luo RC. X-ray repair cross-complementing group 1 Arg399gln gene polymorphism and susceptibility to colorectal cancer: a meta-analysis. Tumour Biol. 2013;34:555–63.CrossRefPubMed
33.
Zurück zum Zitat Wu J, Liu J, Zhou Y, Ying J, Zou H, Guo S, et al. Predictive value of XRCC1 gene polymorphisms on platinum-based chemotherapy in advanced non-small cell lung cancer patients: a systematic review and meta-analysis. Clin Cancer Res. 2012;18:3972–81.CrossRefPubMed Wu J, Liu J, Zhou Y, Ying J, Zou H, Guo S, et al. Predictive value of XRCC1 gene polymorphisms on platinum-based chemotherapy in advanced non-small cell lung cancer patients: a systematic review and meta-analysis. Clin Cancer Res. 2012;18:3972–81.CrossRefPubMed
34.
Zurück zum Zitat Wang L, Yin F, Xu X, Hu X, Zhao D. X-ray repair cross-complementing group 1 (XRCC1) genetic polymorphisms and risk of childhood acute lymphoblastic leukemia: a meta-analysis. PLoS One. 2012;7:e34897.PubMedCentralCrossRefPubMed Wang L, Yin F, Xu X, Hu X, Zhao D. X-ray repair cross-complementing group 1 (XRCC1) genetic polymorphisms and risk of childhood acute lymphoblastic leukemia: a meta-analysis. PLoS One. 2012;7:e34897.PubMedCentralCrossRefPubMed
35.
Zurück zum Zitat Li J, Li Z, Feng L, Guo W, Zhang S. Polymorphisms of DNA repair gene XRCC1 and hepatocellular carcinoma risk among East Asians: a meta-analysis. Tumour Biol. 2013;34:261–9.CrossRefPubMed Li J, Li Z, Feng L, Guo W, Zhang S. Polymorphisms of DNA repair gene XRCC1 and hepatocellular carcinoma risk among East Asians: a meta-analysis. Tumour Biol. 2013;34:261–9.CrossRefPubMed
36.
Zurück zum Zitat Dai L, Duan F, Wang P, Song C, Wang K, Zhang J. XRCC1 gene polymorphisms and lung cancer susceptibility: a meta-analysis of 44 case–control studies. Mol Biol Rep. 2012;39:9535–47.CrossRefPubMed Dai L, Duan F, Wang P, Song C, Wang K, Zhang J. XRCC1 gene polymorphisms and lung cancer susceptibility: a meta-analysis of 44 case–control studies. Mol Biol Rep. 2012;39:9535–47.CrossRefPubMed
Metadaten
Titel
XRCC1 codon 280 polymorphism and susceptibility to lung cancer: a meta-analysis of the literatures
verfasst von
Qin-xiang Guo
Wei-hua Yang
Jin-fang Zhai
Fu-cai Han
Chun-yan Wang
Publikationsdatum
01.10.2013
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 5/2013
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-0863-3

Weitere Artikel der Ausgabe 5/2013

Tumor Biology 5/2013 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.